Graft Versus Host Disease Gvhd Market

DelveInsight’s ‘Graft Versus Host Disease (GvHD) - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the GvHD, historical and forecasted epidemiology as well as the GvHD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.


The GvHD market report provides current treatment practices, emerging drugs, GvHD market share of the individual therapies, current and forecasted GvHD market size from 2018 to 2030 segmented by seven major markets. The Report also covers current GvHD treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

GvHD Disease Understanding and Treatment Algorithm

GvHD Overview

GvHD is an immune condition that occurs when immune cells (T-cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplantation).The two main types of GvHD are acute GvHD and chronic GvHD. Other than this, GvHD is classified into other types, namely: classic acute GvHD, persistent, recurrent, late-onset acute GvHD, classic chronic GvHD, and overlap syndrome and de novo chronic GvHD. Patients who get acute GvHD have a 50% chance of developing chronic GvHD. Acute GvHD (aGvHD) might occur once the donor’s cells have engrafted in the transplant recipient and have been observed to affect skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant.


Acute GvHD is staged and graded (grade 0–IV) by the number and extent of organ involvement (skin, liver, and gastrointestinal). That staging is then used to determine the overall grade of the patient. Usually, patients with grade III–IV acute GvHD have a much worse outcome than those with grade I–II GvHD. The treatment depends on the grade of patient’s GvHD. Chronic GvHD (cGvHD) usually develops later than 100 days after the transplant, and it might occur in the skin, liver, mouth, lungs, gastrointestinal tract, neuromuscular system, or genitourinary tract. Its diagnosis is based on manifestations and not timing. The doctor assesses the GvHD by looking at the number of organs involved and severity. Depending on this, they give it one of the following grades: mild, moderate and severe chronic GvHD. Patients who have an increased risk of developing chronic GvHD are: those who have received stem cells/bone marrow from an HLA mismatched related donor or from an HLA matched unrelated donor, use of peripheral blood stem cells (PBSCs), patients who may have already experienced acute GvHD, older transplant recipients and conditioning regimen..


GvHD Diagnosis

The diagnosis of aGvHD is based wholly on clinical criteria that can be established by biopsy of one of the three target organs. Additionally, laboratory data and/or imaging studies are also useful tests in the diagnostic approach to GvHD. In case of cGvHD, some symptoms might be very ambiguous, which might make the diagnosis possible only after other causes are excluded. Some tests which are useful in diagnosis are biopsy (liver and skin), endoscopy, X-rays and scans, lung function tests and blood tests.


GvHD Treatment

Treatment is grounded on drugs that reduce the body’s immune response and reduce T cells' number. The current hallmark of treatment for GvHD is Immunosuppressant medications. These include both corticosteroid drugs and more advanced medications and techniques that decrease the immune response. Calcineurin Inhibitors (CNIs) are considered to be the backbone of GvHD prophylaxis in HSCT, and can be used as single agents and in combinations as well. Cyclosporine or tacrolimus with short-term methotrexate is mainly used for GvHD prophylaxis in most recipients. Apart from this, immunosuppression using tacrolimus or cyclosporine in combination with mycophenolate mofetil, or sirolimus is also common.

The recommended first-line treatment for both acute and chronic GvHD is systemic steroid therapy (methylprednisolone and prednisone) as a monotherapy and in combinations as well. However, around half of those patients receiving the treatment in first line become refractory to steroid therapy. At present, there are no exact consensus around the management of steroid refractory pool. Ruxolitinib (Jakafi) and Ibrutinib (Imbruvica) are the only two United States Food and Drug Administration (USFDA) approved therapies for the treatment of steroid refractory acute and chronic GvHD, respectively.

GvHD Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted GVHD epidemiology [segmented as Total Hematopoietic stem-cell transplantation (HSCT), Total Allogeneic Transplant cases, Total GvHD cases by Types (Acute and Chronic), Total Incident cases of aGvHD by Grading and organ Involvement, Total Incident cases of cGvHD by Grading and organ involvement, Total Treated patients of GvHD and Mortality adjusted GvHD treated patients] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Country Wise- GvHD Epidemiology

Key Findings

  • In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
  • GvHD is categorized into two types: aGvHD and cGvHD. In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030. Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
  • In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight's analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020
  • The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.

GvHD Drug Chapters

Drug chapter segment of the GvHD report encloses the detailed analysis of GvHD developmental stage pipeline drugs. It also helps to understand the GvHD clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


GvHD Marketed Therapies


Jakafi (Ruxolitinib): Incyte Corporation

Ruxolitinib (INCB018424) is a potent dual JAK1 and JAK2 inhibitor that exhibits low single digit nanomolar biochemical IC50s for both kinases. The USFDA granted an orphan drug designation to Jakafi for the treatment of acute GvHD. Apart from this, in June 2016, the USFDA granted Breakthrough therapy designation for Jakafi in patients with acute GvHD. In May 2019, the USFDA approved Jakafi for the treatment of steroid-refractory GvHD in adult and pediatric patients 12 years and older

Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen


Ibrutinib (previously known as PCI-32765) is a small molecule that works by inhibiting a type of enzyme, called a protein kinase that controls the rate at which certain cells multiply. In particular, ibrutinib has been shown to covalently bind to, and ultimately inhibit, the Bruton’s tyrosine kinase (BTK). In August 2017, the US FDA approved Imbruvica for the treatment of adult patients with chronic GvHD after failure of one or more lines of systemic therapy.


Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics

In September 2015, the Pharmaceuticals and Medical Devices Agency (PMDA) approved Temcell as Japan’s first allogeneic regenerative medical product which was launched in February 2016. Temcell was developed to treat corticosteroid-refractory acute GvHD following hematopoietic stem cell transplantation (corticosteroid therapy is considered to be the first-line treatment for the disease).

Note: Full and detailed list of emerging therapies will be provided in the final report.


GVHD Emerging Drugs


Obnitix (MC0518): Medac

Obnitix, also called MC0518, is a new special preparation of mesenchymal stromal cells (MSC) produced with the help of an innovative process by Medac. Obnitix is administered via an infusion. Apart from this, Obnitix is being studied in an ongoing Phase III (NCT04629833: IDUNN) trial at multiple locations across Germany, France, Poland, and Spain.

MaaT013: MaaT Pharma


MaaT Pharma is developing MaaT013, which is made up of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota manufactured in France, per the GMP requirements. It is an off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. Currently, the company plans to start a multicenter open-label Phase III (NCT04769895) trial, which will begin in October 2021 to evaluate the efficacy of MaaT013 as salvage therapy in acute GvHD patients with gastrointestinal involvement, refractory to ruxolitinib.


Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

Inolimomab is ElsaLys Biotech’s potential therapy for the treatment of steroid-refractory aGvHD. It is an immunotherapy monoclonal antibody that targets the interleukin-2 receptor (IL-2), a chemical molecule named cytokine that contributes to the development and proliferation of some white blood cells, including T-cells responsible for aGvHD. Currently, this drug is in Phase III (NCT04289103) of clinical development. ElsaLys is working on expanding compassionate use programs for inolimomab in several other countries in Europe.


KD025 (Belumosudil): Kadmon Corporation

KD025 (Belumosudil) is a late-stage product candidate who is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes. It has shown potency in the preclinical studies, and as of now, it is being developed in the Phase II clinical trial for the treatment of cGvHD. In March 2021, the USFDA extended the review period for the NDA for belumosudil to treat cGvHD.


CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

CSL 964 AAT, also known as Zemaira, is an Alpha1-Proteinase Inhibitor (A1 -PI) being developed by CSL Behring to treat steroid-refractory, aGvHD and prevention of aGvHD in high-risk patients receiving an allogeneic HSCT.


Itacitinib: Incyte Corporation

Itacitinib by Incyte Corporation is an orally administered small molecule that inhibits JAK 1. Itacitinib is being evaluated in GRAVITAS-309, a pivotal Phase III trial of itacitinib in patients with steroid-naïve chronic GvHD.


MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

MK-7110, formerly known as CD24Fc, was OncoImmune’s lead product, which is now acquired by MSD. It is a first-in-class recombinant fusion protein that targets a novel immune pathway checkpoint. This drug has a dual mechanism of action. A pivotal Phase III (NCT04095858) clinical trial for prophylaxis of GvHD has been initiated nationwide.


EQ001 (Itolizumab; Bmab600): Equillium/Biocon

Itolizumab (EQ001; Bmab600) is a first-in-class immune-modulating antibody therapeutic designed to inhibit CD6, in order to reduce the activation and trafficking of pathogenic T cells that release pro-inflammatory cytokines in a range of autoimmune and inflammatory diseases like aGvHD. Currently, Itolizumab is being studied in Phase I/II (NCT03763318: EQUATE) clinical trial. For next phase, the company expects regulatory interaction in mid-2021 and Phase II/III study initiation is expected in second-half of 2021.

Note: Full and detailed list of emerging therapies will be provided in the final report.

GVHD Market Outlook

Key Findings

The GvHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%. According to the estimates, the highest market size of GVHD is accessed in the United States followed by Japan and Germany, in 2020.


The United States Market Outlook

In United States, the total market size of GvHD is expected to increase at a CAGR of 17.9% during the study period (2018–2030).


EU-5 Countries: Market Outlook

In EU-5, the total market size of GvHD is expected to increase at a CAGR of 15.5% during the study period (2018–2030).


Japan Market Outlook

The total market size of GvHD in Japan is estimated to rise at a CAGR of 5.6%, during the study period (2018–2030).

GvHD Pipeline Development Activities

The drugs which are in pipeline include:


1. Obnitix (MC0518): Medac

2. MaaT013: MaaT Pharma

3. Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

4. SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical

5. KD025 (Belumosudil): Kadmon Corporation

6. Calquence (Acalabrutinib): AstraZeneca

7. Tysabri (Natalizumab): Biogen

8. Efavaleukin Alfa (AMG 592): Amgen

9. Daurismo (Glasdegib): Pfizer

10. AbGn-168H (Neihulizumab): AltruBio

11. CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

12. Itacitinib: Incyte Corporation

13. Entyvio (Vedolizumab; MLN0002): Takeda

14. MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

15. RGI-2001: Regimmune Corporation

16. Defitelio (Defibrotide): Jazz Pharmaceuticals

17. Ninlaro (MLN 9708, MLN2238, Ixazomib): Millennium Pharmaceuticals/Takeda Oncology

18. Gazyva (Obinutuzumab): Roche-Genentech

19. Orencia (Abatacept): Bristol-Myers Squibb

20. T-Guard: Xenikos

21. SYN-004 (ribaxamase): Synthetic Biologics

22. EQ001 (Itolizumab; Bmab600): Equillium/Biocon

23. Pacritinib (Epjevy; ONX-0803): CTI BioPharma

24. Farydak (LBH-589, Panobinostat): Novartis

25. Benlysta (Belimumab): GlaxoSmithKline


Note: Detailed emerging therapies assessment will be provided in the final report

GVHD Drugs Uptake

Analysts Insight

Corticosteroids have always been the mainstay option for the treatment of patients with people suffering from GvHD, and only two agents have been approved by the USFDA in order to treat aGvHD and cGvHD, that too just for a particular segment, each. As per DelveInsight’s market assessment Acute GvHD is the major contributor in the market among prophylaxis, and chronic GvHD, owing to costly approved therapies and also the higher patient population. Aside from this, in Prophylaxis, it is assessed that there is variation in tacrolimus-based regimens usage in United States and EU-5 countries. Due to a lack of FDA or EMA-approved preventive and therapeutic alternatives for aGvHD and cGvHD, new medicines are being developed.

Access and Reimbursement Scenario in GVHD Therapies

In order to make Imbruvica easily accessible to patients, Pharmacyclics and Janssen Biotech offers certain programs with some terms and conditions; eligible patients can get benefit from these programs. The IMBRUVICA By Your Side patient support program is available to help answer some of patient’s questions about the financial aspects of taking IMBRUVICA.

At present, there is a significant need to avoid COVID-19-related hospitalization. NHS England and NHS Improvement have made Ruxolitinib available to lower the risk of getting COVID-19 in GvHD patients. The usual policy-making procedure has been shortened and simplified. This document will be reviewed before July 2021.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the GvHD domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or GvHD market trend. This will support the clients in potential upcoming novel treatment by identifying the over GvHD scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the GvHD Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of GvHD, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the GvHD epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for GvHD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of GvHD market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global GvHD market.

Report Highlights

  • In the coming years, GvHD market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GvHD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for GvHD.
  • Our in-depth analysis of the pipeline assets across different stages of development different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the over GvHD scenario of the research and development activities.

GVHD Report Insights

  • Patient Population
  • Therapeutic Approaches
  • GvHD Pipeline Analysis
  • GvHD Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

GVHD Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • GVHD Epidemiology Segmentation
  • Highly Analyzed Market
  • Drugs Uptake

GVHD Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the GvHD Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the GvHD total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest GvHD market size during the study period (2018–2030)?
  • At what CAGR, the GvHD market is expected to grow in the 7MM during the study period (2018–2030)?
  • What would be the GvHD market outlook across the 7MM during the study period (2018–2030)?
  • What would be the GvHD market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • GvHD patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the GvHD market?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the GvHD?
  • What is the historical GvHD patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of GvHD in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GvHD?
  • Out of GVHD the 7MM countries, which country would have the highest prevalent population of GVHD during the study period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of GvHD?


Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of GvHD?
  • What are the current treatment guidelines for the treatment of GVHD in the US, Europe and Japan?
  • How many companies are developing therapies for the treatment of GvHD?
  • How many therapies are developed by each company for the treatment of GvHD?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of GvHD?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GvHD therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for GvHD and their status?
  • What are the key designations that have been granted for the emerging therapies for GvHD?
  • What is the global historical and forecasted market of GvHD?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the GvHD market.
  • To understand the future market competition in the GvHD market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for GvHD in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for GvHD market.
  • To understand the future market competition in the GvHD market.

1. Key Insights

2. Report Introduction

3. GvHD Market Overview at a Glance

3.1. Market Share (%) Distribution of GvHD in 2018

3.2. Market Share (%) Distribution of GvHD in 2030

4. Executive Summary of GvHD

5. Epidemiology and Market Forecast Flow

6. Disease Background and Overview

6.1. Introduction

6.2. Types of GvHD

6.3. Acute GvHD

6.3.1. Staging of acute GvHD

6.3.2. Grading of acute

6.3.3. Signs and symptoms of acute GvHD

6.3.4. Risk factors for acute GvHD

6.3.5. Pathophysiology of acute GvHD

6.4. Chronic GvHD

6.4.1. Classification of chronic GvHD

6.4.2. Signs and symptoms of chronic GvHD

6.4.3. Risk factors for chronic GvHD

6.4.4. Pathophysiology of chronic GvHD

6.5. Diagnosis of GvHD

6.5.1. Differential diagnosis of GvHD

6.5.2. Diagnostic algorithm

6.5.3. European Society for Blood and Marrow Transplantation (EBMT), position statement on standardized terminology and guidance for GvHD assessment

6.5.4. Comparison of the different guidelines available for chronic GvHD assessment: Overall severity staging

7. Current Treatment

7.1. Treatment algorithm of GvHD

7.2. Treatment Options Currently being used for GvHD

7.3. Extracorporeal photopheresis (ECP)

7.4. Prevention of GvHD

7.5. Treatment and Management Guidelines of GvHD

7.5.1. Recommendations of the European Society for Blood and Marrow Transplantation (EBMT)

7.5.2. Hematopoietic Cell Transplantation, Version 2.2020 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

7.5.3. Guidelines by the British Committee for Standards in Haematology (BCSH) and the British Society of Blood and Marrow Transplantation (BSBMT)

7.5.4. University of Wisconsin Hospitals and Clinics Authority

7.5.5. NHS Recommendations and implications for clinical practice

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Epidemiology Scenario (7MM)

8.3.1. Total Hematopoietic stem-cell transplantation (HSCT) in the 7MM

8.3.2. Total Allogeneic Transplant cases in the 7MM

8.3.3. Total GvHD cases by Types (Acute and Chronic) in the 7MM

8.3.4. Total Incident cases of aGvHD by grading and organ Involvement in the 7MM

8.3.5. Total Incident cases of cGvHD by Grading and organ involvement in the 7MM

8.3.6. Total Treated patients of GvHD in the 7MM

8.3.7. Mortality adjusted GvHD treated patients in the 7MM

8.4. The United States

8.4.1. Total GvHD cases by Types (Acute and Chronic) in the United States

8.4.2. Total Incident cases of aGvHD by Grading and organ Involvement in the United States

8.4.3. Total Incident cases of cGvHD by Grading and organ involvement in the United States

8.4.4. Total Treated patients of GvHD in the United States

8.4.5. Mortality adjusted GvHD treated patients in the United States

8.5. EU-5 Epidemiology

8.6. Germany

8.6.1. Total GvHD cases by Types (Acute and Chronic) in Germany

8.6.2. Total Incident cases of aGvHD by Grading and organ Involvement in Germany

8.6.3. Total Incident cases of cGvHD by Grading and organ involvement in Germany

8.6.4. Total Treated patients of GvHD in Germany

8.6.5. Mortality adjusted GvHD treated patients in Germany

8.7. France

8.7.1. Total GvHD cases by Types (Acute and Chronic) in France

8.7.2. Total Incident cases of aGvHD by Grading and organ Involvement in France

8.7.3. Total Incident cases of cGvHD by Grading and organ involvement in France

8.7.4. Total Treated patients of GvHD in France

8.7.5. Mortality adjusted GvHD treated patients in France

8.8. Italy

8.8.1. Total GvHD cases by Types (Acute and Chronic) in Italy

8.8.2. Total Incident cases of aGvHD by Grading and organ Involvement in Italy

8.8.3. Total Incident cases of cGvHD by Grading and organ involvement in Italy

8.8.4. Total Treated patients of GvHD in Italy

8.8.5. Mortality adjusted GvHD treated patients in Italy

8.9. Spain

8.9.1. Total GvHD cases by Types (Acute and Chronic) in Spain

8.9.2. Total Incident cases of aGvHD by Grading and organ Involvement in Spain

8.9.3. Total Incident cases of cGvHD by Grading and organ involvement in Spain

8.9.4. Total Treated patients of GvHD in Spain

8.9.5. Mortality adjusted GvHD treated patients in Spain

8.10. The United Kingdom

8.10.1. Total GvHD cases by Types (Acute and Chronic) in the United Kingdom

8.10.2. Total Incident cases of aGvHD by Grading and organ Involvement in the United Kingdom

8.10.3. Total Incident cases of cGvHD by Grading and organ involvement in the United Kingdom

8.10.4. Total Treated patients of GvHD in the United Kingdom

8.10.5. Mortality adjusted GvHD treated patients in the United Kingdom

8.11. Japan Epidemiology

8.11.1. Total GvHD cases by Types (Acute and Chronic) in Japan

8.11.2. Total Incident cases of aGvHD by Grading and organ Involvement in Japan

8.11.3. Total Incident cases of cGvHD by Grading and organ involvement in Japan

8.11.4. Total Treated patients of GvHD in Japan

8.11.5. Mortality adjusted GvHD treated patients in Japan

9. Patient Journey

10. Key Endpoints for GvHD

11. Marketed Drugs: Key cross

11.1. Jakafi (Ruxolitinib): Incyte Corporation

11.1.1. Product Description

11.1.2. Regulatory Milestones

11.1.3. Other Developmental Activities

11.1.4. Pivotal Clinical Trial

11.1.5. Ongoing Current Pipeline Activity

11.1.6. Safety and Efficacy

11.2. Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trial

11.2.5. Ongoing Current Pipeline Activity

11.3. Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Eficacy

12. Emerging Therapies

12.1. Key Cross of Emerging Therapies

12.2. Obnitix (MC0518): Medac

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.3. MaaT013: MaaT Pharma

12.3.1. Product Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.4. Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

12.4.1. Product Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.4. Safety and Efficacy

12.5. SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical

12.5.1. Product Description

12.5.2. Other Developmental Activities

12.5.3. Clinical Development

12.5.4. Safety and Efficacy

12.6. KD025 (Belumosudil): Kadmon Corporation

12.6.1. Product Description

12.6.2. Other Developmental Activities

12.6.3. Clinical Development

12.6.4. Safety and Efficacy

12.7. Arscimed (arsenic trioxide): Medsenic

12.7.1. Product Description

12.7.2. Other Developmental Activities

12.7.3. Clinical Development

12.7.4. Safety and Efficacy

12.8. Calquence (Acalabrutinib): AstraZeneca

12.8.1. Product Description

12.8.2. Clinical Development

12.9. Tysabri (Natalizumab): Biogen

12.9.1. Product Description

12.9.2. Clinical Development

12.9.3. Safety and Efficacy

12.10. Efavaleukin Alfa (AMG 592): Amgen

12.10.1. Product Description

12.10.2. Clinical Development

12.11. Daurismo (Glasdegib): Pfizer

12.11.1. Product Description

12.11.2. Clinical Development

12.12. AbGn-168H (Neihulizumab): AltruBio

12.12.1. Product Description

12.12.2. Other Developmental Activities

12.12.3. Clinical Development

12.12.4. Safety and Eficacy

12.13. CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

12.13.1. Product Description

12.13.2. Other Developmental Activities

12.13.3. Clinical Development

12.13.4. Safety and Efficacy

12.14. Itacitinib: Incyte Corporation

12.14.1. Product Description

12.14.2. Other Developmental Activities

12.14.3. Clinical Development

12.14.4. Safety and Efficacy

12.15. Entyvio (Vedolizumab; MLN0002): Takeda

12.15.1. Product Description

12.15.2. Other Developmental Activities

12.15.3. Clinical Development

12.15.4. Safety and Efficacy

12.16. MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

12.16.1. Product Description

12.16.2. Other Developmental Activities

12.16.3. Clinical Development

12.16.4. Safety and Efficacy

12.17. RGI-2001: Regimmune Corporation

12.17.1. Product Description

12.17.2. Other Developmental Activities

12.17.3. Clinical Development

12.17.4. Safety and Efficacy

12.18. Defitelio (Defibrotide): Jazz Pharmaceuticals

12.18.1. Product Description

12.18.2. Other Developmental Activities

12.18.3. Clinical Development

12.19. Ninlaro (MLN 9708, MLN2238, Ixazomib): Millennium Pharmaceuticals/Takeda Oncology

12.19.1. Product Description

12.19.2. Other Developmental Activities

12.19.3. Clinical Development

12.19.4. Safety and Efficacy

12.20. Gazyva (Obinutuzumab): Roche-Genentech

12.20.1. Product Description

12.20.2. Clinical Development

12.21. Orencia (Abatacept): Bristol-Myers Squibb

12.21.1. Product Description

12.21.2. Other Developmental Activities

12.21.3. Clinical Development

12.21.4. Safety and Efficacy

12.22. T-Guard: Xenikos

12.22.1. Product Description

12.22.2. Other Developmental Activities

12.22.3. Clinical Development

12.22.4. Safety and Efficacy

12.23. SYN-004 (ribaxamase): Synthetic Biologics

12.23.1. Product Description

12.23.2. Other Developmental Activities

12.23.3. Clinical Development

12.24. EQ001 (Itolizumab; Bmab600): Equillium/Biocon

12.24.1. Product Description

12.24.2. Other Developmental Activities

12.24.3. Clinical Development

12.24.4. Safety and Efficacy

12.25. Pacritinib (Epjevy; ONX-0803): CTI BioPharma

12.25.1. Product Description

12.25.2. Clinical Development

12.25.3. Safety and Efficacy

12.26. Farydak (LBH-589, Panobinostat): Novartis

12.26.1. Product Description

12.26.2. Clinical Development

12.26.3. Safety and Efficacy

12.27. BMS-986004 (Letolizumab): Bristol-Myers Squibb

12.27.1. Product Description

12.27.2. Clinical Development

12.28. Benlysta (Belimumab): GlaxoSmithKline

12.28.1. Product Description

12.28.2. Clinical Development

13. GvHD: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. 7MM Market Size

13.3.1. Total Market Size of GvHD in the 7MM

13.3.2. Market Size of GvHD by Types in the 7MM

13.3.3. Market size of aGvHD by therapies in the 7MM

13.3.4. Market size of cGvHD by therapies in the 7MM

13.3.5. Market Size of GvHD by Prophylaxis in the 7MM

13.4. The United States Market Size

13.4.1. Total Market size of GvHD in the United States

13.4.2. Total Market size of GvHD by Types in the United States

13.4.3. Market size of aGvHD by therapies in the United States

13.4.4. Market size of cGvHD by therapies in the United States

13.4.5. Market Size of GvHD by Prophylaxis in the United States

13.5. EU-5 Market Size

13.6. Germany

13.6.1. Total Market size of GvHD in Germany

13.6.2. Market size of GvHD by Types in Germany

13.6.3. Market size of aGvHD by therapies in Germany

13.6.4. Market size of cGvHD by therapies in Germany

13.6.5. Market Size of GvHD by Prophylaxis in Germany

13.7. France

13.7.1. Total Market size of GvHD in France

13.7.2. Market size of GvHD by Types in France

13.7.3. Market size of aGvHD by therapies in France

13.7.4. Market size of cGvHD by therapies in France

13.7.5. Market Size of GvHD by Prophylaxis in France

13.8. Italy

13.8.1. Total Market size of GvHD in Italy

13.8.2. Market size of GvHD by Types in Italy

13.8.3. Market size of aGvHD by therapies in Italy

13.8.4. Market size of cGvHD by therapies in Italy

13.8.5. Market Size of GvHD by Prophylaxis in Italy

13.9. Spain

13.9.1. Total Market size of GvHD in Spain

13.9.2. Market size of GvHD by Types in Spain

13.9.3. Market size of aGvHD by therapies in Spain

13.9.4. Market size of cGvHD by therapies in Spain

13.9.5. Market Size of GvHD by Prophylaxis in Spain

13.10. The United Kingdom

13.10.1. Total Market size of GvHD in the United Kingdom

13.10.2. Market size of GvHD by Types in the United Kingdom

13.10.3. Market size of aGvHD by therapies in the United Kingdom

13.10.4. Market size of cGvHD by therapies in the United Kingdom

13.10.5. Market Size of GvHD by Prophylaxis in the United Kingdom

13.11. Japan

13.11.1. Total Market size of GvHD in Japan

13.11.2. Market size of GvHD by Types in Japan

13.11.3. Market size of aGvHD by therapies in Japan

13.11.4. Market size of cGvHD by therapies in Japan

13.11.5. Market Size of GvHD by Prophylaxis in Japan

14. Market Access and Reimbursement

14.1. National Institute for Health and Care Excellence (NICE) Assessment: The United Kingdom

14.2. The Centers for Medicare and Medicaid Services (CMS)

14.3. NHS England

14.4. France

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet needs

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of GvHD; Market, Epidemiology, and Key Events (2018–2030)

Table 2: Extent of organ involvement

Table 3: Overall clinical grade (based on most severe target organ involvement)

Table 4: Total Hematopoietic stem-cell transplantation (HSCT) in the 7MM (2018–2030)

Table 5: Total Allogeneic Transplant cases in the 7MM (2018–2030)

Table 6: Total GvHD cases by Types (Acute and Chronic) in the 7MM (2018–2030)

Table 7: Total Incident cases of aGvHD by Grading in the 7MM (2018–2030)

Table 8: Total Incident cases of aGvHD by organ involvement in the 7MM (2018–2030)

Table 9: Total Incident cases of cGvHD by Grading in the 7MM (2018–2030)

Table 10: Total Incident cases of cGvHD by organ involvement in the 7MM (2018–2030)

Table 11: Total Treated patients of GvHD in the 7MM (2018–2030)

Table 12: Mortality adjusted GvHD treated patients in the 7MM (2018–2030)

Table 13: Total GvHD cases by Types (Acute and Chronic) in the United States (2018–2030)

Table 14: Total Incident cases of aGvHD by Grading in the United States (2018–2030)

Table 15: Total Incident cases of aGvHD by organ involvement in the United States (2018–2030)

Table 16: Total Incident cases of cGvHD by Grading in the United States (2018–2030)

Table 17: Total Incident cases of cGvHD by organ involvement in the United States (2018–2030)

Table 18: Total Treated patients of GvHD in the United States (2018–2030)

Table 19: Mortality adjusted GvHD treated patients in the United States (2018–2030)

Table 20: Total GvHD cases by Types (Acute and Chronic) in Germany (2018–2030)

Table 21: Total Incident cases of aGvHD by Grading in Germany (2018–2030)

Table 22: Total Incident cases of aGvHD by organ involvement in Germany (2018–2030)

Table 23: Total Incident cases of cGvHD by Grading in Germany (2018–2030)

Table 24: Total Incident cases of cGvHD by organ involvement in Germany (2018–2030)

Table 25: Total Treated patients of GvHD in Germany (2018–2030)

Table 26: Mortality adjusted GvHD treated patients in Germany (2018–2030)

Table 27: Total GvHD cases by Types (Acute and Chronic) in France (2018–2030)

Table 28: Total Incident cases of aGvHD by Grading in France (2018–2030)

Table 29: Total Incident cases of aGvHD by organ involvement in France (2018–2030)

Table 30: Total Incident cases of cGvHD by Grading in France (2018–2030)

Table 31: Total Incident cases of cGvHD by organ involvement in France (2018–2030)

Table 32: Total Treated patients of GvHD in France (2018–2030)

Table 33: Mortality adjusted GvHD treated patients in France (2018–2030)

Table 34: Total GvHD cases by Types (Acute and Chronic) in Italy (2018–2030)

Table 35: Total Incident cases of aGvHD by Grading in Italy (2018–2030)

Table 36: Total Incident cases of aGvHD by organ involvement in Italy (2018–2030)

Table 37: Total Incident cases of cGvHD by Grading in Italy (2018–2030)

Table 38: Total Incident cases of cGvHD by organ involvement in Italy (2018–2030)

Table 39: Total Treated patients of GvHD in Italy (2018–2030)

Table 40: Mortality adjusted GvHD treated patients in Italy (2018–2030)

Table 41: Total GvHD cases by Types (Acute and Chronic) in Spain (2018–2030)

Table 42: Total Incident cases of aGvHD by Grading in Spain (2018–2030)

Table 43: Total Incident cases of aGvHD by organ involvement in Spain (2018–2030)

Table 44: Total Incident cases of cGvHD by Grading in Spain (2018–2030)

Table 45: Total Incident cases of cGvHD by organ involvement in Spain (2018–2030)

Table 46: Total Treated patients of GvHD in Spain (2018–2030)

Table 47: Mortality adjusted GvHD treated patients in Spain (2018–2030)

Table 48: Total GvHD cases by Types (Acute and Chronic) in the United Kingdom (2018–2030)

Table 49: Total Incident cases of aGvHD by Grading in the United Kingdom (2018–2030)

Table 50: Total Incident cases of aGvHD by organ involvement in the United Kingdom (2018–2030)

Table 51: Total Incident cases of cGvHD by Grading in the United Kingdom (2018–2030)

Table 52: Total Incident cases of cGvHD by organ involvement in the United Kingdom(2018–2030)

Table 53: Total Treated patients of GvHD in the United Kingdom (2018–2030)

Table 54: Mortality adjusted GvHD treated patients in the United Kingdom (2018–2030)

Table 55: Total GvHD cases by Types (Acute and Chronic) in Japan (2018–2030)

Table 56: Total Incident cases of aGvHD by Grading in Japan (2018–2030)

Table 57: Total Incident cases of aGvHD by organ involvement in Japan (2018–2030)

Table 58: Total Incident cases of cGvHD by Grading in Japan (2018–2030)

Table 59: Total Incident cases of cGvHD by organ involvement in Japan (2018–2030)

Table 60: Total Treated patients of GvHD in Japan (2018–2030)

Table 61: Mortality adjusted GvHD treated patients in Japan (2018–2030)

Table 62: Revised Definitions of Biomarkers

Table 63: Ruxolitinib, Clinical Trial Description, 2021

Table 64: Ibrutinib, Clinical Trial Description, 2021

Table 65: Remestemcel-L, Clinical Trial Description, 2021

Table 66: Obnitix (MC0518), Clinical Trial Description, 2021

Table 67: MaaT013, Clinical Trial Description, 2021

Table 68: Leukotac, Clinical Trial Description, 2021

Table 69: SNDX-6532, Clinical Trial Description, 2021

Table 70: KD025, Clinical Trial Description, 2021

Table 71: Arsenic Trioxide Injectable Solution, Clinical Trial Description, 2021

Table 72: Calquence, Clinical Trial Description, 2021

Table 73: Tysabri, Clinical Trial Description, 2021

Table 74: Efavaleukin Alfa, Clinical Trial description, 2021

Table 75: Daurismo, Clinical Trial Description, 2021

Table 76: AbGn-168H, Clinical Trial Description, 2021

Table 77: CSL 964, Clinical Trial Description, 2021

Table 78: Itacitinib, Clinical Trial Description, 2021

Table 79: Entyvio, Clinical Trial Description, 2021

Table 80: MK-7110, Clinical Trial Description, 2021

Table 81: RGI-2001, Clinical Trial Description, 2021

Table 82: Defitelio, Clinical Trial Description, 2021

Table 83: Ninlaro, Clinical Trial Description, 2021

Table 84: Obinutuzumab, Clinical Trial Description, 2021

Table 85: Orencia, Clinical Trial Description, 2021

Table 86: T-Guard, Clinical Trial Description, 2021

Table 87: SYN-004, Clinical Trial Description, 2021

Table 88: EQ001, Clinical Trial Description, 2021

Table 89: Pacritinib, Clinical Trial Description, 2021

Table 90: Farydak, Clinical Trial Description, 2021

Table 91: BMS-986004, Clinical Trial Description, 2021

Table 92: Benlysta, Clinical Trial Description, 2021

Table 93: Market Size of GvHD in the 7MM in USD Million (2018–2030)

Table 94: 7MM GvHD market size by types, in USD Million (2018–2030)

Table 95: 7MM Market size of GvHD by therapies, in USD Million (2018–2030)

Table 96: 7MM Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 97: 7MM Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 98: Market Size of GvHD by Prophylaxis in the 7MM, USD Million (2018–2030)

Table 99: Market Size of GvHD in the United States in USD Million (2018–2030)

Table 100: The United States GvHD market size by types, in USD Million (2018–2030)

Table 101: The United States Market size of GvHD by therapies, in USD Million (2018–2030)

Table 102: The United States Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 103: The United States Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 104: Market Size of GvHD by Prophylaxis in the United States, USD Million (2018–2030)

Table 105: Market Size of GvHD in Germany in USD Million (2018–2030)

Table 106: Germany GvHD market size by types, in USD Million (2018–2030)

Table 107: Germany Market size of GvHD by therapies, in USD Million (2018–2030)

Table 108: Germany Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 109: Germany Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 110: Market Size of GvHD by Prophylaxis in Germany USD Million (2018–2030)

Table 111: Market Size of GvHD in France in USD Million (2018–2030)

Table 112: France GvHD market size by types, in USD Million (2018–2030)

Table 113: France Market size of GvHD by therapies, in USD Million (2018–2030)

Table 114: France Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 115: France Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 116: Market Size of GvHD by Prophylaxis in France USD Million (2018–2030)

Table 117: Market Size of GvHD in Italy in USD Million (2018–2030)

Table 118: Italy GvHD market size by types, in USD Million (2018–2030)

Table 119: Italy Market size of GvHD by therapies, in USD Million (2018–2030)

Table 120: Italy Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 121: Italy Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 122: Market Size of GvHD by Prophylaxis in Italy USD Million (2018–2030)

Table 123: Market Size of GvHD in Spain in USD Million (2018–2030)

Table 124: Spain GvHD market size by types, in USD Million (2018–2030)

Table 125: Spain Market size of GvHD by therapies, in USD Million (2018–2030)

Table 126: Spain Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 127: Spain Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 128: Market Size of GvHD by Prophylaxis in Spain, USD Million (2018–2030)

Table 129: Market Size of GvHD in the United Kingdom in USD Million (2018–2030)

Table 130: The United Kingdom GvHD market size by types, in USD Million (2018–2030)

Table 131: The United Kingdom Market size of GvHD by therapies, in USD Million (2018–2030)

Table 132: The United Kingdom Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 133: The United Kingdom Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 134: Market Size of GvHD by Prophylaxis in the United Kingdom, in USD Million (2018–2030)

Table 135: Market Size of GvHD in Japan, in USD Million (2018–2030)

Table 136: Japan GvHD market size by types, in USD Million (2018–2030)

Table 137: Japan Market size of GvHD by therapies, in USD Million (2018–2030)

Table 138: Japan Market size of aGvHD by therapies, in USD Million (2018–2030)

Table 139: Japan Market size of cGvHD by therapies, in USD Million (2018–2030)

Table 140: Market Size of GvHD by Prophylaxis in Japan, USD Million (2018–2030)

List of Figures

Figure 1: Process of Allogeneic stem cell transplantation

Figure 2: National Institutes of Health (NIH) consensus guidelines schema illustrating the classification into different types of GvHD (quality) and severity that applies to all subtypes.

Figure 3: Acute GvHD initiation phase

Figure 4: Summary of the complete pathophysiology of aGvHD

Figure 5: Liver Biopsy procedure

Figure 6: Diagnostic algorithm for acute GvHD

Figure 7: Diagnostic algorithm according to NIH

Figure 8: Diagnosis/Workup of GvHD by National Comprehensive Cancer Network (NCCN)

Figure 9: Treatment algorithm summarizing initial treatment of aGvHD

Figure 10: An algorithm showing possible treatment options for cGvHD

Figure 11: Recommended diagnostic algorithm for patients with suspected gastrointestinal acute GvHD after HSCT

Figure 12: Management of acute GvHD by NCCN

Figure 13: Management of chronic GvHD by NCCN

Figure 14: Novel drug agents in patients with cGvHD

Figure 15: Risk Factors of GvHD

Figure 16: Total Hematopoietic stem-cell transplantation (HSCT) in the 7MM (2018–2030)

Figure 17: Total Allogeneic Transplant cases in the 7MM (2018–2030)

Figure 18: Total GvHD cases by Types (Acute and Chronic) in the 7MM (2018–2030)

Figure 19: Total Incident cases of aGvHD by Grading in the 7MM (2018–2030)

Figure 20: Total Incident cases of aGvHD by organ involvement in the 7MM (2018–2030)

Figure 21: Total Incident cases of cGvHD by Grading in the 7MM (2018–2030)

Figure 22: Total Incident cases of cGvHD by organ involvement in the 7MM (2018–2030)

Figure 23: Total Treated patients of aGvHD in the 7MM (2018–2030)

Figure 24: Total Treated patients of cGvHD in the 7MM (2018–2030)

Figure 25: Mortality adjusted GvHD treated patients in the 7MM (2018–2030)

Figure 26: Total GvHD cases by Types (Acute and Chronic) in the United States (2018–2030)

Figure 27: Total Incident cases of aGvHD by Grading in the United States (2018–2030)

Figure 28: Total Incident cases of aGvHD by organ involvement in the United Kingdom 2018–2030)

Figure 29: Total Incident cases of cGvHD by Grading in the United States (2018–2030)

Figure 30: Total Incident cases of cGvHD by organ involvement in the United States (2018–2030)

Figure 31: Total Treated patients of aGvHD in the United States (2018–2030)

Figure 32: Total Treated patients of cGvHD in the United States (2018–2030)

Figure 33: Mortality adjusted GvHD treated patients in the United States (2018–2030)

Figure 34: Total GvHD cases by Types (Acute and Chronic) in Germany (2018–2030)

Figure 35: Total Incident cases of aGvHD by Grading in Germany (2018–2030)

Figure 36: Total Incident cases of aGvHD by organ involvement in Germany (2018–2030)

Figure 37: Total Incident cases of cGvHD by Grading in Germany (2018–2030)

Figure 38: Total Incident cases of cGvHD by organ involvement in Germany (2018–2030)

Figure 39: Total Treated patients of aGvHD in Germany 2018–2030)

Figure 40: Total Treated patients of cGvHD in Germany 2018–2030)

Figure 41: Mortality adjusted GvHD treated patients in Germany (2018–2030)

Figure 42: Total GvHD cases by Types (Acute and Chronic) in France (2018–2030)

Figure 43: Total Incident cases of aGvHD by Grading in France (2018–2030)

Figure 44: Total Incident cases of aGvHD by organ involvement in France (2018–2030)

Figure 45: Total Incident cases of cGvHD by Grading in France (2018–2030)

Figure 46: Total Incident cases of cGvHD by organ involvement in France (2018–2030)

Figure 47: Total Treated patients of aGvHD in France (2018–2030)

Figure 48: Total Treated patients of cGvHD in France (2018–2030)

Figure 49: Mortality adjusted GvHD treated patients in France (2018–2030)

Figure 50: Total GvHD cases by Types (Acute and Chronic) in Italy (2018–2030)

Figure 51: Total Incident cases of aGvHD by Grading in Italy (2018–2030)

Figure 52: Total Incident cases of aGvHD by organ involvement in Italy (2018–2030)

Figure 53: Total Incident cases of cGvHD by Grading in Italy (2018–2030)

Figure 54: Total Incident cases of cGvHD by organ involvement in Italy (2018–2030)

Figure 55: Total Treated patients of aGvHD in Italy (2018–2030)

Figure 56: Total Treated patients of cGvHD in Italy (2018–2030)

Figure 57: Mortality adjusted GvHD treated patients in Italy (2018–2030)

Figure 58: Total GvHD cases by Types (Acute and Chronic) in Spain (2018–2030)

Figure 59: Total Incident cases of aGvHD by Grading in Spain (2018–2030)

Figure 60: Total Incident cases of aGvHD by organ involvement in Spain (2018–2030)

Figure 61: Total Incident cases of cGvHD by Grading in Spain (2018–2030)

Figure 62: Total Incident cases of cGvHD by organ involvement in Spain (2018–2030)

Figure 63: Total Treated patients of aGvHD in Spain (2018–2030)

Figure 64: Total Treated patients of cGvHD in Spain (2018–2030)

Figure 65: Mortality adjusted GvHD treated patients in Spain (2018–2030)

Figure 66: Total GvHD cases by Types (Acute and Chronic) in the United Kingdom (2018–2030)

Figure 67: Total Incident cases of aGvHD by Grading in the United Kingdom (2018–2030)

Figure 68: Total Incident cases of aGvHD by organ involvement in the United Kingdom (2018–2030)

Figure 69: Total Incident cases of cGvHD by Grading in the United Kingdom (2018–2030)

Figure 70: Total Incident cases of cGvHD by organ involvement in the United Kingdom (2018–2030)

Figure 71: Total Treated patients of aGvHD in the United Kingdom (2018–2030)

Figure 72: Total Treated patients of cGvHD in the United Kingdom (2018–2030)

Figure 73: Mortality adjusted GvHD treated patients in the United Kingdom (2018–2030)

Figure 74: Total GvHD cases by Types (Acute and Chronic) in Japan (2018–2030)

Figure 75: Total Incident cases of aGvHD by Grading in Japan (2018–2030)

Figure 76: Total Incident cases of aGvHD by organ involvement in Japan (2018–2030)

Figure 77: Total Incident cases of cGvHD by Grading in Japan (2018–2030)

Figure 78: Total Incident cases of cGvHD by organ involvement in Japan (2018–2030)

Figure 79: Total Treated patients of aGvHD in Japan (2018–2030)

Figure 80: Total Treated patients of cGvHD in Japan (2018–2030)

Figure 81: Mortality adjusted GvHD treated patients in Japan (2018–2030)

Figure 82: Patient Journey

Figure 83: Leukotac Mechanism of Action

Figure 84: Belumosudil’s Mechanism of action

Figure 85: Gazyva’s way of working

Figure 86: Market Size of GvHD in the 7MM, USD Million (2018–2030)

Figure 87: 7MM GvHD market size by types, in USD Million (2018–2030)

Figure 88: Market size of aGvHD by therapies in the 7MM, in USD Million (2018–2030)

Figure 89: Market size of cGvHD by therapies in the 7MM, in USD Million (2018–2030)

Figure 90: Market Size of GvHD by Prophylaxis in the 7MM, USD Million (2018–2030)

Figure 91: Market Size of GvHD in the United States, USD Million (2018–2030)

Figure 92: The United States Market size of GvHD by Types, in USD Million (2018–2030)

Figure 93: Market size of aGvHD by therapies in the United States, in USD Million (2018–2030)

Figure 94: Market size of cGvHD by therapies in the United States, in USD Million (2018–2030)

Figure 95: Market Size of GvHD by Prophylaxis in the United States ,USD Million (2018–2030)

Figure 96: Market Size of GvHD in Germany, USD Million (2018–2030)

Figure 97: Germany Market size of GvHD by Types, in USD Million (2018–2030)

Figure 98: Market size of aGvHD by therapies in Germany, in USD Million (2018–2030)

Figure 99: Market size of cGvHD by therapies in Germany, in USD Million (2018–2030)

Figure 100: Market Size of GvHD by Prophylaxis in Germany USD Million (2018–2030)

Figure 101: Market Size of GvHD in France, USD Million (2018–2030)

Figure 102: France Market size of GvHD by Types, in USD Million (2018–2030)

Figure 103: Market size of aGvHD by therapies in France, in USD Million (2018–2030)

Figure 104: Market size of cGvHD by therapies in France, USD Million (2018–2030)

Figure 105: Market Size of GvHD by Prophylaxis in France USD Million (2018–2030)

Figure 106: Market Size of GvHD in Italy, USD Million (2018–2030)

Figure 107: Italy Market size of GvHD by Types, in USD Million (2018–2030)

Figure 108: Market size of aGvHD by therapies in Italy, in USD Million (2018–2030)

Figure 109: Market size of GvHD by chronic in Italy, in USD Million (2018–2030)

Figure 110: Market Size of GvHD by Prophylaxis in Italy USD Million (2018–2030)

Figure 111: Market Size of GvHD in Spain, USD Million (2018–2030)

Figure 112: Spain Market size of GvHD by Types, in USD Million (2018–2030)

Figure 113: Market size of aGvHD by therapies in Spain, in USD Million (2018–2030)

Figure 114: Market size of cGvHD by therapies in Spain, in USD Million (2018–2030)

Figure 115: Market Size of GvHD by Prophylaxis in Spain, USD Million (2018–2030)

Figure 116: Market Size of GvHD in the United Kingdom, USD Million (2018–2030)

Figure 117: The United Kingdom Market size of GvHD by Types, in USD Million (2018–2030)

Figure 118: Market size of aGvHD by therapies in the United Kingdom, in USD Million (2018–2030)

Figure 119: Market size of cGvHD by therapies in the United Kingdom, in USD Million 2018–2030)

Figure 120: Market Size of GvHD by Prophylaxis in the United Kingdom, USD Million (2018–2030)

Figure 121: Market Size of GvHD in Japan, USD Million (2018–2030)

Figure 122: Japan Market size of GvHD by Types, in USD Million (2018–2030)

Figure 123: Market size of aGvHD by therapies in Japan, in USD Million (2018–2030)

Figure 124: Market size of cGvHD by therapies in Japan, in USD Million (2018–2030)

Figure 125: Market Size of GvHD by Prophylaxis in Japan, USD Million (2018–2030)

• Medac

• MaaT Pharma

• ElsaLys Biotech (Mediolanum Farmaceutici Spa)

• Syndax Pharmaceutical

• Kadmon Corporation

• AstraZeneca

• Biogen

• Amgen

• Pfizer

• AltruBio

• CSL Behring

• Incyte Corporation

• Takeda

• OncoImmune/Merck (MSD)

• Regimmune Corporation

• Jazz Pharmaceuticals

• Millennium Pharmaceuticals/Takeda Oncology

• Roche-Genentech

• Bristol-Myers Squibb

• Xenikos

• Synthetic Biologics

• Equillium/Biocon

• CTI BioPharma

• Novartis

• GlaxoSmithKline

  • Tags:
  • Graft Versus Host Disease (GvHD) ma...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) p...
  • Graft Versus Host Disease (GvHD) t...
  • Graft Versus Host Disease (GvHD) d...
  • Graft Versus Host Disease (GvHD) s...
  • Graft Versus Host Disease (GvHD) m...
  • Graft Versus Host Disease (GvHD) d...
  • Graft Versus Host Disease (GvHD) e...
  • Graft Versus Host Disease (GvHD)

Forward to Friend

Need A Quote